CN107495362A - A kind of Diabetic Nephropathy patients nutriment - Google Patents
A kind of Diabetic Nephropathy patients nutriment Download PDFInfo
- Publication number
- CN107495362A CN107495362A CN201710649713.4A CN201710649713A CN107495362A CN 107495362 A CN107495362 A CN 107495362A CN 201710649713 A CN201710649713 A CN 201710649713A CN 107495362 A CN107495362 A CN 107495362A
- Authority
- CN
- China
- Prior art keywords
- diabetic nephropathy
- nutriment
- prebiotics
- fruit
- probiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 30
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 30
- 239000000835 fiber Substances 0.000 claims abstract description 16
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 16
- 239000006041 probiotic Substances 0.000 claims abstract description 16
- 235000018291 probiotics Nutrition 0.000 claims abstract description 16
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 11
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 11
- 229920001503 Glucan Polymers 0.000 claims description 3
- 241000209140 Triticum Species 0.000 claims 2
- 235000021307 Triticum Nutrition 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 101000994673 Urodacus yaschenkoi Potassium channel toxin alpha-KTx 6.21 Proteins 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 201000001421 hyperglycemia Diseases 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 229940121657 clinical drug Drugs 0.000 abstract description 3
- 238000002651 drug therapy Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000037157 Azotemia Diseases 0.000 description 3
- 201000000523 end stage renal failure Diseases 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 208000009852 uremia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 208000028208 end stage renal disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- -1 inflammatory factor Chemical compound 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a kind of Diabetic Nephropathy patients nutriment, including following components：Fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics.Because fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics regulation human body intestinal canal flora balance can target " insulin resistance path " by fat metabolism approach, improve the high fat of blood in diabetic nephropathy source and the symptom of hyperglycaemia；Suppress urotoxic generation by targetting " inflammation urotoxin path " simultaneously, so as to play protection renal, prevent the effect that sb.'s illness took a turn for the worse.It is a kind of novel therapeutic mode for safely and effectively aiding in existing clinical drug therapy diabetic nephropathy.
Description
Technical field
The present invention relates to a kind of Diabetic Nephropathy patients nutriment.
Background technology
Chronic renal disease turns into a kind of major disease for threatening global human health.American-European countries's chronic renal disease
The incidence of disease between 6~16%, as the ESRD (uremia) caused by chronic renal disease in global morbidity
Rate improves year by year, and poor prognosis, spends height, heavy burden is brought to global Health Investment.With China's national economy and health
Report the incidence of disease of chronic renal disease in the big cities such as the development of cause, the raising of living standards of the people, Shanghai, Beijing, Guangzhou
It is similar to developed country, even more high.At present, the dialysis center of Chinese situation of all-level hospitals is more overstaffed, to family and state's family property
Political affairs bring heavy burden.Diabetes have become the maximum seed of trouble for causing chronic renal disease at present, account for overall pathogenic factor
More than 35%.Diabetic nephropathy is one of most important complication of diabetic.The incidence of disease in China is also in rising trend, mesh
Preceding first reason for turning into End-stage renal disease.
Diabetic nephropathy is that the hyperglycaemia of diabetes causes renal function lesion caused by kidney Microangiopathy.Due to
Complicated metabolic disorder also be present in it, once End-stage renal disease is developed into, often than the treatment more spine of other kidney troubles
Hand, therefore a kind of effective therapeutic modality of new type of safe is found for delaying the significant of diabetic nephropathy.
The content of the invention：
The present invention provides a kind of Diabetic Nephropathy patients nutriment, to solve existing kind of Diabetic Nephropathy patients nutrition
Product can not play protection renal, prevent the technical problem that sb.'s illness took a turn for the worse.
In order to solve the above technical problems, the present invention adopts the technical scheme that：
A kind of Diabetic Nephropathy patients nutriment, it is characterized in that, including following components：Fruit-vegetable fibre, prebiotics, oat
Glucan and probiotics.
The fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics proportion are respectively：
Fruit-vegetable fibre 40%-60%
Prebiotics 10%-30%
Bitter Melon P.E 5%-15%
Probiotics 10%-30%.
Diabetic Nephropathy patients nutriment no longer contains other components.
The fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics proportion are respectively：
Fruit-vegetable fibre 50%
Prebiotics 20%
Oat beta-glucan 10%
Probiotics 20%.
After above-mentioned technical proposal is employed, because fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics adjust human body
Gut flora balance can target " insulin resistance path " by fat metabolism approach, improve the high blood in diabetic nephropathy source
The symptom of fat and hyperglycaemia；Suppress urotoxic generation by targetting " inflammation urotoxin path " simultaneously, protected so as to play kidney
Shield, prevents the effect that sb.'s illness took a turn for the worse.It is a kind of safely and effectively to aid in existing the new of clinical drug therapy diabetic nephropathy to control
Treatment mode.Nutriment novelty of the present invention by suppress " insulin resistance path " solve diabetic nephropathy it is intractable by
In the state of an illness caused by metabolic disorder is unmanageable the problem of, also suppress to cause uremia to be produced by targetting " inflammation urotoxin path "
Raw urotoxic generation.So as to play protection renal, prevent the effect that sb.'s illness took a turn for the worse.
Embodiment
A kind of Diabetic Nephropathy patients nutriment, including following components：Fruit-vegetable fibre, prebiotics, oat beta-glucan and
Probiotics.Fruit-vegetable fibre, prebiotics, oat beta-glucan and probiotics proportion are respectively：
Fruit-vegetable fibre 40%-60%
Prebiotics 10%-30%
Oat beta-glucan 5%-15%
Probiotics 10%-30%
The specific proportioning such as following table of each component (so that gross weight is 100 grams as an example)：
Because human oral's nutriment amount is limited, especially patient, this Diabetic Nephropathy patients do not contain it with nutriment
Best results during its component, it is evident that due to being nutriment, being mixed into other harmless components can certainly.This hair
Bright nutriment, it is mainly used in the auxiliary treatment of diabetic nephropathy, and it can be led to by adjusting human body intestinal canal flora balance
Fat metabolism approach targeting " insulin resistance path " is crossed, improves the high fat of blood in diabetic nephropathy source and the symptom of hyperglycaemia；
Suppress urotoxic generation by targetting " inflammation urotoxin path " simultaneously, so as to play protection renal, prevent what sb.'s illness took a turn for the worse
Effect.It is a kind of novel therapeutic mode for safely and effectively aiding in existing clinical drug therapy diabetic nephropathy.
1st, the mechanism of action of recipe ingredient
Target " insulin resistance path "
" insulin resistance " is the unmanageable basic reason of the blood glucose of diabetes, and hyperglycaemia causes skin lesion in tiny blood vessels
Evil, glomerulus vascular lesion is shown as in kidney, causes albuminuria, blood urine, and clinic is referred to as diabetic nephropathy.It is of the present invention
Nutriment is balanced by adjusting gut flora, improves fat metabolic disturbance environment.Disorders of lipid metabolism such as high triglyceride and Gao You
Closely related from fatty acidaemia etc. and insulin resistance, hypertriglyceridemia and high free fatty acid hyperlipemia further aggravate
Insulin resistance.By improving fat metabolism path, suppress the generation of bile acid, inflammatory factor, TMAO, releasing causes
The adverse factor of pancreas islet resistance.Meanwhile by improving fat metabolism path, promote the generation of short chain fatty acids, increase insulin
Sensitiveness.So as to be controlled from source because sb.'s illness took a turn for the worse for diabetic nephropathy caused by complicated metabolic disorder.
Target " inflammation urotoxin path "
The generation of inflammation and urotoxic generation, it is to cause the arch-criminal that sb.'s illness took a turn for the worse in chronic kidney disease.Kidney and intestines
Two-way interaction between road flora be present, referred to as intestines-kidney axle bacterium will produce some potential toxic metabolites, and slow
Property nephrosis may influence the composition of gut flora and destroy gut barrier function, promote endotoxin and bacterium to enter blood from enteric cavity
Circulation.Nutriment of the present invention is balanced by adjusting gut flora, is protected the integrality of intestinal mucosa, is directly suppressed " inflammation
The activation of uremia path ", reduce because diet and bacteriogenic inflammatory factor and urotoxin enter blood by " intestines-kidney axle "
Liquid circulates, and inducing chronic kidney disease, sb.'s illness took a turn for the worse, or even uremic generation.
Synergy mechanism
Diabetic nephropathy, it is both that diabetes hyperglycaemia causes kidney injury caused by Microangiopathy, and it is a kind of tight
The chronic renal disease of weight.Therefore, effective treatment needs to take into account the common feature of diabetes and chronic kidney disease.The present invention passes through
Regulation and control for gut flora balance, not only targeting " insulin resistance path " solve the problems, such as diabetes, also may be used
The puzzlement constantly deteriorated with targeting " inflammation urotoxin path " solution chronic kidney disease.Meanwhile " insulin resistance path "
Improve the reduction that can promote that urotoxin generates in " inflammation urotoxin path ", suppress the deterioration of chronic kidney disease and uremic hair
It is raw.The protection of gut barrier in " inflammation urotoxin path ", can " insulin resistance path " provide play one's part to the full
Place.Therefore, the regulation and control that nutriment of the present invention is balanced by gut flora, targeting " insulin resistance path " and
" inflammation urotoxin path ", can effective auxiliary treatment diabetic nephropathy.
Claims (4)
1. a kind of Diabetic Nephropathy patients nutriment, it is characterized in that, including following components：Fruit-vegetable fibre, prebiotics, oat Portugal
Glycan and probiotics.
2. Diabetic Nephropathy patients nutriment as claimed in claim 1, it is characterized in that, the fruit-vegetable fibre, prebiotics, swallow
Wheat glucan and probiotics proportion are respectively：
Fruit-vegetable fibre 40%-60%
Prebiotics 10%-30%
Oat beta-glucan 5%-15%
Probiotics 10%-30%.
3. Diabetic Nephropathy patients nutriment as claimed in claim 1 or 2, it is characterized in that, the Diabetic Nephropathy patients
No longer contain other components with nutriment.
4. Diabetic Nephropathy patients nutriment as claimed in claim 3, it is characterized in that, the fruit-vegetable fibre, prebiotics, swallow
Wheat glucan and probiotics proportion are respectively：
Fruit-vegetable fibre 50%
Prebiotics 20%
Oat beta-glucan 10%
Probiotics 20%.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710649713.4A CN107495362A (en) | 2017-08-02 | 2017-08-02 | A kind of Diabetic Nephropathy patients nutriment |
| PCT/CN2017/105663 WO2019024248A1 (en) | 2017-08-02 | 2017-10-11 | Nutritional product for diabetic nephropathy patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710649713.4A CN107495362A (en) | 2017-08-02 | 2017-08-02 | A kind of Diabetic Nephropathy patients nutriment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107495362A true CN107495362A (en) | 2017-12-22 |
Family
ID=60690288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710649713.4A Pending CN107495362A (en) | 2017-08-02 | 2017-08-02 | A kind of Diabetic Nephropathy patients nutriment |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107495362A (en) |
| WO (1) | WO2019024248A1 (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101317666A (en) * | 2008-07-18 | 2008-12-10 | 罗文礼 | High-efficiency composite food cellulose and preparation method thereof |
| CN102448478A (en) * | 2009-03-25 | 2012-05-09 | 科·汉森有限公司 | Use of probiotics to ameliorate diet-induced insulin resistance |
| CN102550916A (en) * | 2012-02-04 | 2012-07-11 | 王姗思 | Food for treating diabetic nephropathy (DN) |
| CN104664329A (en) * | 2015-03-04 | 2015-06-03 | 益点堂（上海）生物科技有限公司 | Sugar-free probiotics powder and preparation method thereof |
| CN105661547A (en) * | 2016-01-22 | 2016-06-15 | 湖南营养树科技有限公司 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
| CN106418544A (en) * | 2016-06-30 | 2017-02-22 | 山东凤凰生物有限公司 | Protein and probiotic composite food with weight losing effect |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN106689959A (en) * | 2017-01-10 | 2017-05-24 | 唐山金鼎盛生物科技有限公司 | Solid beverage for assisting blood glucose regulation |
| CN106954862A (en) * | 2017-03-31 | 2017-07-18 | 北京市永康年健康科技有限责任公司 | Edible fiber products and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106173829A (en) * | 2016-07-06 | 2016-12-07 | 武汉好多多生物科技有限公司 | A kind of processing method of ourishing rice flour |
| CN106666728A (en) * | 2016-12-23 | 2017-05-17 | 上海奥医生物医药科技有限公司 | Special clinical nutrient composition for gestational diabetes and preparation method of nutrient composition |
-
2017
- 2017-08-02 CN CN201710649713.4A patent/CN107495362A/en active Pending
- 2017-10-11 WO PCT/CN2017/105663 patent/WO2019024248A1/en active Application Filing
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101317666A (en) * | 2008-07-18 | 2008-12-10 | 罗文礼 | High-efficiency composite food cellulose and preparation method thereof |
| CN102448478A (en) * | 2009-03-25 | 2012-05-09 | 科·汉森有限公司 | Use of probiotics to ameliorate diet-induced insulin resistance |
| CN102550916A (en) * | 2012-02-04 | 2012-07-11 | 王姗思 | Food for treating diabetic nephropathy (DN) |
| CN104664329A (en) * | 2015-03-04 | 2015-06-03 | 益点堂（上海）生物科技有限公司 | Sugar-free probiotics powder and preparation method thereof |
| CN105661547A (en) * | 2016-01-22 | 2016-06-15 | 湖南营养树科技有限公司 | Probiotics and Bombyx mori compounded diabetic patient nutritional supplement |
| CN106418544A (en) * | 2016-06-30 | 2017-02-22 | 山东凤凰生物有限公司 | Protein and probiotic composite food with weight losing effect |
| CN106619743A (en) * | 2016-12-28 | 2017-05-10 | 山东龙力生物科技股份有限公司 | Probiotic solid drink with hypoglycaemic effect and preparation method of probiotic solid drink |
| CN106689959A (en) * | 2017-01-10 | 2017-05-24 | 唐山金鼎盛生物科技有限公司 | Solid beverage for assisting blood glucose regulation |
| CN106954862A (en) * | 2017-03-31 | 2017-07-18 | 北京市永康年健康科技有限责任公司 | Edible fiber products and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019024248A1 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201912170A (en) | Use of Bacteroides gracilis to inhibit obesity | |
| CN102441081A (en) | Medicament for treating gout and its preparation method | |
| KR20140116988A (en) | A pharmaceutical composition for preventing and treating rheumarthritis and lipid metabolism related disease containing Methyl Sulfonyl Methane | |
| ES2949270T3 (en) | Use of a pharmaceutical carrier in the preparation of an antidiabetic pharmaceutical composition comprising berberine and oryzanol | |
| JP2023506322A (en) | Lithium ion composition and its use | |
| CN107495362A (en) | A kind of Diabetic Nephropathy patients nutriment | |
| CN109125361A (en) | A kind of compound reducing the gentle solution acute gout arthritis symptom of high lithemia | |
| CN102688363A (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN110420225A (en) | A kind of composition and its preparation method and application for preventing and treating osteoarthritis | |
| CN102188699A (en) | Pharmaceutical composition for treating atherosclerosis, and preparation method and application thereof | |
| CN100411650C (en) | A compound capsule for treating Bi syndrome | |
| Barraclough et al. | Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial) | |
| CN101856377A (en) | Compound preparation for treating nephrotic syndromes | |
| CN106619697A (en) | Drug for treating cirrhosis with ascites, preparation method thereof and application | |
| JP2001086953A (en) | Analgesic food for assisting health | |
| WO2019239963A1 (en) | Pharmaceutical composition for treating chronic constipation | |
| CN104411319A (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| JP2005524604A (en) | Oral preparation containing activated carbon and use thereof | |
| CN110946905B (en) | Traditional Chinese medicine composition applied to acupuncture points of peritoneal dialysis patients and preparation method and application thereof | |
| CN102846750A (en) | Fengtongning composite preparation and preparation method thereof | |
| CN107281192A (en) | A kind of composition for mitigating, treating and prevent rheumatoid arthritis | |
| Traunero et al. | Administration of bicarbonates through percutaneous gastrostomy with continuous nocturnal infusion in a patient with Kearns-Sayre disease: a life changing therapeutical paradigm | |
| CN105250641A (en) | Traditional Chinese medicine composition for treating rheumatism | |
| CN106389439A (en) | Chinese and western medicine composition for curing liver cirrhosis ascites, and preparation method and application thereof | |
| CANAKIS et al. | Key Concepts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |